[Results of the use of vasoactive preparation pikamilon in pigmented retinal abiotrophy].
Eighty patients with pigmented retinal abiotrophy (PRA) and 20 controls were examined. The perfusion pressure and arteriovenous coefficient are markedly reduced in patients with stages 1-2 PRA, in comparison with controls. Deterioration of the visual function in patients with stages 3-4 PRA vs. that in stages 1-2 was associated with a more marked reduction of the hemodynamic parameters and the status of ocular vessels. Pikamilon therapy in a dose of 2 ml of 10% solution once a day intramuscularly for 10 days led to improvement of the visual function and ocular hemodynamics in patients with PRA. Treatment efficacy was higher in patients with disease stages 1-2. Pikamilon is recommended for the treatment of patients with PRA.
D000293:Adolescent; D000328:Adult; D000368:Aged; D005260:Female; D006801:Humans; D007273:Injections, Intramuscular; D008297:Male; D008875:Middle Aged; D012161:Retinal Artery / Q000187:drug effects*; D012162:Retinal Degeneration / Q000188:drug therapy*; D012174:Retinitis Pigmentosa / Q000188:drug therapy; D012996:Solutions; D013997:Time Factors; D014665:Vasodilator Agents / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D014792:Visual Acuity; D014794:Visual Fields; D005680:gamma-Aminobutyric Acid / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use
D012996:Solutions; D014665:Vasodilator Agents; C044905:nicotinoyl-GABA; D005680:gamma-Aminobutyric Acid
Rezul'taty primeneniia vazoaktivnogo preparata pikamilona pri pigmentnoĭ abiotrofii setchatki.